The role of GLYR1 in tumors was first reported in 2012 by Alhopuro et al., who found that GLYR1 had a mutation frequency of 51% in MSI CRC and presumed it to be a novel tumor suppressor [5]. This evidence concerns the gene GLYR1 and colorectal carcinoma.